Bortezomib Leads to More Complete Remissions in Patients With High-Risk Follicular Lymphoma

Monday, June 6, 2016

Andrew M. Evens, DO, MSc, on the early results of ECOG-ACRIN E2408 trial, which found that adding bortezomib to standard bendamustine-rituximab treatment increases the number of complete remissions in patients with high-risk lymphoma.

September 2019, Volume 5, Issue 11

August 2019, Volume 5, Issue 10

July 2019 Bonus Mid-Year Edition, Volume 5, Issue 9

July 2019, Volume 5, Issue 8

Bortezomib Leads to More Complete Remissions in Patients With High-Risk Follicular Lymphoma

Recent Articles

Fathers (and Mothers) of Hematology

Pretransplant Bridging With Blinatumomab Reduces MRD in Children With B-Cell Acute Lymphocytic Leukemia

Michaela Liedtke, MD

Prashant Kapoor, MD

Possible Delays for Landmark Opioid Trial, U.S. Judge Denies Drug Companies’ Dismissals

Current Issue

September 2019, Volume 5, Issue 11

Meeting Coverage

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

RADIUS: Midostaurin Reduces Post-Transplant Relapse Risk in FLT3-Mutated AML

Editor`s Corner

Fathers (and Mothers) of Hematology

Our Identity Crisis